Navigation Links
Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
Date:10/7/2008

ceptor screening, side effect profiling, functional cellular assays, in vivo efficacy studies using IVIS technology, and in vivo pharmacodynamic analysis.

"PathHunter eXpress Beta-Arrestin kits for use with Caliper's LabChip instruments contain everything needed to perform screening or profiling experiments: cells, detection reagents, media and plates. The workflow improvements inherent to this complete solution for live-cell GPCR experiments enables scientists to spend more of their time designing better and safer drugs," said Sailaja Kuchibhatla, Senior Vice President of Business Development at DiscoveRx. "Today's announcement further signifies the momentum generated by our partnership with Caliper and the relationships they are helping us develop with customers in secondary screening and profiling laboratories."

About DiscoveRx Inc.

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of Beta-Galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. For more information on DiscoveRx products, please visit http://www.discoverx.com.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
2. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
3. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
4. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
5. Caliper Life Sciences Reports Second Quarter 2008 Results
6. Caliper Life Sciences Second Quarter 2008 Financial Results Conference Call Notice
7. Caliper Life Sciences Added to Russell 3000(R) Index
8. Caliper Life Sciences to Present at Deutsche Banks 33rd Annual Health Care Conference
9. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
10. Caliper Life Sciences Reports West Coast Consolidation of Operations
11. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Reportlinker Adds Biotechnology Instrumentation - International Market Trends 2Reportlinker Adds Biotechnology Instrumentation - International Market Trends 3Reportlinker Adds Biotechnology Instrumentation - International Market Trends 4Reportlinker Adds Biotechnology Instrumentation - International Market Trends 5Reportlinker Adds Biotechnology Instrumentation - International Market Trends 6Reportlinker Adds Biotechnology Instrumentation - International Market Trends 7SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project 2Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4